FDA approves Alyftrek once-daily oral combination for cystic fibrosis Dr. Kamal Kant Kohli23 Dec 2024 8:45 AM ISTThe US Food and Drug Administration has approved Alyftrek, a once-daily oral combination of vanzacaftor, tezacaftor, and deutivacaftor, for the...
ERS Conference Highlights: ChatGPT Surpassed Trainee Doctors in Assessing Complex Respiratory Illness In Children Dr. Garima Soni10 Sept 2024 8:45 AM ISTThe chatbot ChatGPT performed better than trainee doctors in assessing complex cases of respiratory disease in areas such as cystic fibrosis, asthma,...
ChatGPT outperforms trainee doctors in assessing complex respiratory illness in children, reveals research Dr. Kamal Kant Kohli9 Sept 2024 8:00 PM ISTThe chatbot ChatGPT performed better than trainee doctors in assessing complex cases of respiratory disease in areas such as cystic fibrosis, asthma...
Ivacaftor Safe and Effective for Infants with Cystic Fibrosis Aged 1 to <4 Months, reveals study Dr Riya Dave19 July 2024 9:00 PM ISTIn an open-label phase 3 study, researchers report that ivacaftor (IVA) is safe and effective in treating cystic fibrosis in infants aged 1 to less...
Repeated GA Shows No Negative Neurobehavioral Effects in Children with Cystic Fibrosis, suggests Lancet study Dr Riya Dave19 Jun 2024 8:00 AM ISTResearchers have found that repeated exposure to general anesthesia does not negatively impact neurobehavioral outcomes in children with cystic...
Medical Bulletin 24/February/2024 Anshika Mishra24 Feb 2024 3:00 PM ISTHere are the top medical news highlights for the day:New zinc discovery offers promise for cystic fibrosis patients Researchers from the University...
New zinc discovery offers promise for cystic fibrosis patients Anshika Mishra23 Feb 2024 5:15 PM ISTResearchers from the University of Queensland have discovered a fault in the bacteria-killing function of immune cells in people with Cystic Fibrosis...
Phlegm's colour can indicate degree of inflammation in the lungs and predict outcomes for bronchiectasis patients Dr. Kamal Kant Kohli3 Oct 2023 8:00 PM ISTUK: The study of nearly 20,000 patients from 31 countries revealed that the colour of the phlegm (also known as sputum) may provide clinically...
Elexacaftor-tezacaftor-ivacaftor therapy provides relief from chronic rhinosinusitis in patients with cystic fibrosis: JAMA Dr. Kamal Kant Kohli19 Sept 2023 8:00 PM ISTUSA: Treatment with elexacaftor-tezacaftor-ivacaftor (ETI; Trikafta) therapy is associated with improved chronic sinus disease and clinical outcomes...
Bacterial and fungal infections may increase risk of lung infections due to P. aeruginosa in children with CF Niveditha Subramani13 July 2023 8:30 PM ISTAmongst all infectious agents, Pseudomonas aeruginosa (Pa) remains the most frequently isolated pathogen in the airways of adults with Cystic fibrosis...
Person-to-person transmission not a dominant mode of infection for Mycobacterium abscessus Dr. Kamal Kant Kohli4 Jun 2023 8:00 PM ISTStudy suggests person-to-person transmission may not be the dominant mode of infection for an aggressive lung pathogen.USA: Recent research found that...
FDA approves TRIKAFTA for children with Cystic Fibrosis as well Dr. Kamal Kant Kohli1 May 2023 4:45 AM ISTThe Food and Drug administration has expanded the approval of elexacaftor, tezacaftor, and ivacaftor (Trikafta) in cystic fibrosis to include even...
